Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases.

As landmark advances in blood-based Alzheimer’s diagnostics, digital biomarkers, multimodal approaches, and precision medicine continue to reshape the field, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification, demonstrate target engagement, generate earlier efficacy signals, and de-risk CNS drug development programmes.

Companies attending the Novel CNS Biomarkers Summit Europe:

• Roche

• UCB

• Lundbeck

• Servier

• NRG Therapeutics

• Immunic Therapeutics

• Progenra

• Saniona

• Bial

…and more!

Why attend the Novel CNS Biomarkers Summit Europe?

• Join 60+ biomarker and translational medicine leaders

• Gain insights from 17+ expert speakers

• Explore biomarker strategies across 6+ CNS indications

• Participate in interactive workshops and networking opportunities

Discover the brand-new event programme now for more information on sessions and how to register your place.